These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11733269)

  • 1. The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy.
    Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group
    Ophthalmology; 2001 Dec; 108(12):2266-72. PubMed ID: 11733269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a growth hormone receptor antagonist on proliferative diabetic retinopathy.
    Chantelau E
    Ophthalmology; 2002 Dec; 109(12):2187; author reply 2187-8. PubMed ID: 12466154
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
    Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
    Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
    Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
    Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy.
    Yin D; Vreeland F; Schaaf LJ; Millham R; Duncan BA; Sharma A
    Clin Cancer Res; 2007 Feb; 13(3):1000-9. PubMed ID: 17289896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
    Higham CE; Atkinson AB; Aylwin S; Bidlingmaier M; Drake WM; Lewis A; Martin NM; Moyes V; Newell-Price J; Trainer PJ
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1187-93. PubMed ID: 22278424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Growth hormone receptor antagonists: potential indications].
    Muller AF; Janssen JA; de Herder WW; van der Lely AJ
    Ned Tijdschr Geneeskd; 2001 Jan; 145(2):69-73. PubMed ID: 11225259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
    Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
    Trainer PJ; Drake WM; Katznelson L; Freda PU; Herman-Bonert V; van der Lely AJ; Dimaraki EV; Stewart PM; Friend KE; Vance ML; Besser GM; Scarlett JA; Thorner MO; Parkinson C; Klibanski A; Powell JS; Barkan AL; Sheppard MC; Malsonado M; Rose DR; Clemmons DR; Johannsson G; Bengtsson BA; Stavrou S; Kleinberg DL; Cook DM; Phillips LS; Bidlingmaier M; Strasburger CJ; Hackett S; Zib K; Bennett WF; Davis RJ
    N Engl J Med; 2000 Apr; 342(16):1171-7. PubMed ID: 10770982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice.
    McCutcheon IE; Flyvbjerg A; Hill H; Li J; Bennett WF; Scarlett JA; Friend KE
    J Neurosurg; 2001 Mar; 94(3):487-92. PubMed ID: 11235955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.
    van der Lely AJ; Hutson RK; Trainer PJ; Besser GM; Barkan AL; Katznelson L; Klibanski A; Herman-Bonert V; Melmed S; Vance ML; Freda PU; Stewart PM; Friend KE; Clemmons DR; Johannsson G; Stavrou S; Cook DM; Phillips LS; Strasburger CJ; Hackett S; Zib KA; Davis RJ; Scarlett JA; Thorner MO
    Lancet; 2001 Nov; 358(9295):1754-9. PubMed ID: 11734231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SYSTEMIC INTERLEUKIN 1β INHIBITION IN PROLIFERATIVE DIABETIC RETINOPATHY: A Prospective Open-Label Study Using Canakinumab.
    Stahel M; Becker M; Graf N; Michels S
    Retina; 2016 Feb; 36(2):385-91. PubMed ID: 26218500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapy of diabetic retinopathy with somatostatin analogues].
    Lang GE
    Ophthalmologe; 2004 Mar; 101(3):290-3. PubMed ID: 15007609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy.
    Simó R; Lecube A; Segura RM; García Arumí J; Hernández C
    Am J Ophthalmol; 2002 Sep; 134(3):376-82. PubMed ID: 12208249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals.
    Adamis AP; Altaweel M; Bressler NM; Cunningham ET; Davis MD; Goldbaum M; Gonzales C; Guyer DR; Barrett K; Patel M;
    Ophthalmology; 2006 Jan; 113(1):23-8. PubMed ID: 16343627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth.
    Divisova J; Kuiatse I; Lazard Z; Weiss H; Vreeland F; Hadsell DL; Schiff R; Osborne CK; Lee AV
    Breast Cancer Res Treat; 2006 Aug; 98(3):315-27. PubMed ID: 16541323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
    Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study).
    Jorge R; Costa RA; Calucci D; Cintra LP; Scott IU
    Retina; 2006; 26(9):1006-13. PubMed ID: 17151487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression of retinopathy after improved metabolic control in type 2 diabetic patients. Relation to IGF-1 and hemostatic variables.
    Henricsson M; Berntorp K; Berntorp E; Fernlund P; Sundkvist G
    Diabetes Care; 1999 Dec; 22(12):1944-9. PubMed ID: 10587823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy.
    Marazuela M; Lucas T; Alvarez-Escolá C; Puig-Domingo M; de la Torre NG; de Miguel-Novoa P; Duran-Hervada A; Manzanares R; Luque-Ramírez M; Halperin I; Casanueva FF; Bernabeu I
    Eur J Endocrinol; 2009 Apr; 160(4):535-42. PubMed ID: 19147599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.